China is serious about medicine. Universal access to basic healthcare, an improving IP environment, Chinese companies desire for innovation and substantial funding opportunities are opening up possibilities for Western companies of all sizes. Despite this, biotech’s business development priorities are US, EU and Japan.
Now, it’s time to engage with China. By Robert Johnson (Partner) and Li Zeng (Consultant)
>>> Read More (download whitepaper)